A best evidence topic in cardiac surgery was written according to a structured protocol. The question addressed was, in adult patients undergoing cardiac surgery requiring extracorporeal cardiopulmonary bypass (CPB), does administration of desmopressin acetate (DDAVP) reduce postoperative blood loss and transfusion requirements? Altogether 38 papers were found using the reported search, of which 19 represented the best evidence to answer the clinical question. The authors, journal, date and country of publication, patient group studied, study type, relevant outcomes and results of these papers are tabulated. Perioperative administration of DDAVP in adult patients undergoing cardiac surgery requiring CPB may result in a small but significant reduction in postoperative blood loss. However, this does not translate into a reproducible, clinically significant reduction in exposure to transfusion in unselected patients exposed to CPB. Several sub-groups of patients have been identified in whom DDAVP reduces postoperative blood loss and transfusion requirements. These sub-groups include patients who have received preoperative aspirin within 7 days of surgery, patients with CPB times in excess of 140 min and patients with demonstrable pre-or perioperative platelet dysfunction as determined by TEG analysis or platelet function assays. Platelet dysfunction at the time of surgery may be secondary to preoperative administration of antiplatelet medications, the result of pathological processes such as von Willebrands disease, uraemia or aortic stenosis with its associated sheer stress, as well as operative variables such as prolonged exposure to CPB. The evidence does not support the routine use of DDAVP in all cardiac surgery; indeed, it is clear that there is no significant reduction in postoperative blood loss or transfusion requirements with the administration of DDAVP in patients undergoing isolated coronary artery bypass grafting (CABG) in the absence of the features noted above. Given the absence of a clinically significant reduction in exposure to blood transfusion in unselected patients, we cannot recommend the routine use of DDAVP in patients exposed to CPB. However, DDAVP may reduce postoperative bleeding in patients who have received preoperative aspirin within 7 days of surgery, patients with CPB times in excess of 140 min and patients with demonstrable platelet dysfunction and should be used selectively in these subgroups.
INTRODUCTION
A best evidence topic was constructed according to a structured protocol. This is fully described in the ICVTS [1] .
THREE-PART QUESTION
In adult patients undergoing cardiac surgery with CPB, does administration of DDAVP reduce postoperative blood loss and transfusion requirements?
CLINICAL SCENARIO
You have weaned the patient from CPB following a complicated and subsequently prolonged elective aortic valve replacement for severe aortic stenosis. The patient had been taking aspirin in the week prior to the operation. Despite appropriate reversal of heparin, the patient continues to have extensive coagulopathic bleeding. The anaesthetist suggests that DDAVP may be of benefit in terms of reducing blood loss and transfusion requirements postoperatively. You resolve to review the literature. Blood loss in DDAVP group 1215 ± 381 ml vs placebo group 1637 ± 761 ml; P = 0.0097 Red-cell transfusion in the first 24 h in DDAVP and placebo groups was 600 ml (95% CI: 300-1830) vs 600 ml (95% CI: 300-2100), respectively; P = 0.53/NS Postoperative transfusion (all products) requirements (24 h)
Continued
Transfusion in the first 24 h in DDAVP and placebo groups was 1025 ml (95% CI: 300-4140) vs 860 ml (95% CI: 247-5346), respectively; P = 0.23/NS 

RESULTS
The papers included have been divided based on the types of procedures included in the studies: (i) 14 studies of isolated CABG;
(ii) 8 studies of mixed cases with isolated CABG included; (iii) 3 studies of mixed cases with isolated CABG excluded and (iv) 1 study of isolated aortic valve replacement. Results from three meta-analyses are also presented.
Fourteen studies of patients undergoing isolated coronary artery bypass grafting
Within the meta-analyses performed by Cattaneo et al. [2] , Levi et al. [3] and Carless et al. [4] , 14 RCTs investigated the administration of DDAVP in 818 patients undergoing isolated CABG. Ten of these trials found no significant difference in postoperative blood loss or transfusion requirements with DDAVP. Of the four remaining RCTs [5] [6] [7] [8] , three [5] [6] [7] were trials where administration of preoperative aspirin was an inclusion criterion. Gratz et al. [5] and Sheridan et al. [6] looked at patients who had received aspirin within 7 days of their elective CABG. Both found significant reductions in combined intra-and postoperative blood loss with DDAVP. Sheridan et al. [6] also found a significant reduction in postoperative exposure to transfusion with DDAVP. Dilthey et al. [7] looked at patients who had aspirin within 5 days of their elective CABG operation. Despite no significant reduction in postoperative blood loss, they did find a significant reduction in postoperative transfusion requirements with DDAVP. Mongan et al. [8] identified a subgroup of patients with platelet dysfunction on the basis of post-CPB maximal amplitude on TEG analysis, who had significantly reduced postoperative blood loss with DDAVP. From these results, we can conclude that in the absence of either preoperative aspirin administration or demonstrable platelet dysfunction, there is no benefit from DDAVP in terms of postoperative blood loss or transfusion requirements in patients undergoing isolated CABG.
Eight studies of mixed cases with isolated coronary artery bypass grafting included A further eight RCTs [9] [10] [11] [12] [13] [14] [15] [16] investigated the use of DDAVP in 789 patients undergoing a variety of cardiac operations including isolated CABG. Seven of these trials [9] [10] [11] [12] [13] [14] [15] documented the numbers of each type of operation performed, of which six trials [9] [10] [11] [12] [13] [14] had a predominance of isolated CABG. Of these six trials, five [9] [10] [11] [12] [13] found no significant difference in postoperative blood loss or transfusion requirements with DDAVP. Given the findings of the RCTs in patients undergoing isolated CABG, it is not surprising that the RCTs with mixed cases, and a predominance of CABG operations have similar results. Despite this, several subgroups within these 'mixed RCTs' have been shown to benefit from DDAVP.
Depotis et al. [14] identified a subgroup of patients with platelet dysfunction on the basis of post-CPB clot ratios using a point-of-care platelet function assay (hemoSTATUS), who had significantly reduced postoperative blood loss and transfusion requirements with DDAVP.
Casas et al. [15] identified a subgroup with prolonged CPB time >120 min who had significantly reduced postoperative blood loss with DDAVP. Temeck et al. [16] demonstrated a significant increase in postoperative blood loss in the placebo group with prolonged CPB >90 min compared with <60 min, while no such increase occurred in the DDAVP group. No subgroup analyses were performed with regard to transfusion requirements.
Three studies of mixed cases with isolated coronary artery bypass grafting excluded Three RCTs [17] [18] [19] investigated the use of DDAVP in patients undergoing a variety of cardiac procedures excluding isolated CABG. Salzman et al. [17] showed a significant reduction in combined intra-and postoperative blood loss of 900 ml with DDAVP, yet despite this no significant difference in transfusion requirements. Rocha et al. [18] and Ansell et al. [19] both found no significant difference in postoperative blood loss or transfusion requirements with DDAVP; however, they make no note of preoperative aspirin administration, subgroup analysis based on CPB time or platelet function analysis.
One study of isolated aortic valve replacement
Steinlechner et al. [20] limited their investigation to patients undergoing aortic valve replacement for severe aortic stenosis with platelet dysfunction on the basis of a platelet function analyser (PFA 100). They demonstrated a significant decrease in postoperative blood loss with DDAVP. However, this did not translate to a significant difference in postoperative transfusion requirements. and 1679 patients, with a 68, 65 and 71% predominance of isolated CABG, respectively. These meta-analyses all found a small but significant reduction in postoperative blood loss of 9%, 114 and 97 ml, respectively, with DDAVP. Only Carless et al. [4] found any difference in terms of postoperative transfusion requirements with a small but significant reduction of 0.39 units with DDAVP; despite this, there was no difference noted in exposure to blood transfusion. They also noted the decrease in blood loss was greater in patients with aspirin administration within 7 days of operation and those with CPB times >140 min. It is possible larger effects in the identified subgroups mentioned previously may have been diluted by the inclusion of a large proportion of patients undergoing isolated CABG in these meta-analyses.
CLINICAL BOTTOM LINE
Given the absence of a clinically significant reduction in exposure to blood transfusion in unselected patients, we cannot recommend the routine use of DDAVP in patients exposed to CPB. However, DDAVP may reduce postoperative bleeding in patients who have received preoperative aspirin within 7 days of surgery, patients with CPB times in excess of 140 min and patients with demonstrable platelet dysfunction, and should be used selectively in these subgroups.
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